Key facts
- This page summarizes Gabrielle Sulzberger's Form 4 filing for Cerevel Therapeutics Holdings, Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Aug 2024, 16:32.
Gabrielle Sulzberger - 01 Aug 2024 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 01 Aug 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Aug 2024, 16:32:15 UTC
- Prior SEC filing
- 16 Jul 2024
- Next SEC filing
- 20 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Bodenrader, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Gabrielle Sulzberger filed Form 4 for Cerevel Therapeutics Holdings, Inc. on 05 Aug 2024.
Change
- Previous filing in this sequence was filed on 16 Jul 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CERE
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -48,415
- Change %
- -82%
- Price
- Shares after
- 10,461
- Date
- 01 Aug 2024
- Ownership
- Direct
- Footnotes
- F1
CERE
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -10,461
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 01 Aug 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CERE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -95,242
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 01 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 95,242
- Exercise price
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Gabrielle Sulzberger is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.
Footnote F2
These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
Footnote F3
At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.